<DOC>
	<DOCNO>NCT03030001</DOCNO>
	<brief_summary>This single-arm , open-label , one center , dose escalation clinical study , determine safety efficacy infusion autologous T cell engineer express immune checkpoint antibody chimeric antigen receptor target mesothelin adult patient mesothelin positive , recurrent refractory malignant tumor .</brief_summary>
	<brief_title>PD-1 Antibody Expressing CAR T Cells Mesothelin Positive Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>1 . Relapsed refractory advance solid malignancy . 2 . Progressive disease response current therapy . 3 . Patients must previously receive least one standard therapy cancer ( available ) either nonresponders ( progressive disease ) recur . And patient willing attend clinical trial . 4 . Gender unlimited , age 18 year 80 year . 5 . Life expectancy≥6 month . 6 . ECOG ( Eastern Cooperative Oncology Group ) performance status 02 . 7 . Adequate venous access apheresis , contraindication leukapheresis ; Peripheral venous access ；no contraindication lymphocyte separation . 8 . IHC ( immunohistochemistry ) result tumor tissue： mesothelin positive ：frequency≥2，intensity≥2 + . The percentage tumor cell nuclei stain ( 0 , stain ; 1 , ≤10 % ; 2 , 1050 % 3 , &gt; 50 % ) staining intensity ( range 0 3+ ) . 9 . Adequate hepatic function , renal function bone marrow function：WBC≥3.0×109/L , PLT≥60×109/L , HGB≥85g/L , LY≥0.7×109/L ; Alanine aminotransferase/Aspartate transaminase ( ALT/AST ) 2.5 time upper limit normal value , total bilirubin ( TBiL ) 1times upper limit normal value , Serum creatinine1.5 time upper limit normal value . 10 . Willing able understand sign Informed Consent Document . 11 . Women childbearing age must evidence negative pregnancy test . Patients must willing practice birth control four month follow treatment . 1 . Life expectancy6 month . 2 . Patients uncontrolled active infection exclude . 3 . Patients severe heart lung dysfunction ; uncontrolled hypertension , unstable coronary disease evidence uncontrolled arrhythmia , unstable angina , decompensated congestive heart failure ( &gt; New York Heart Association Class II ) , myocardial infarction within 6 month study exclude ; aberrant pulmonary function testing : forced expiratory volume ( FEV ) &lt; 30 % ( predict ) , diffusion capacity lung carbon monoxide ( DLCO ) ( correct ) &lt; 30 % oxyhemoglobin saturation90 % exclude . 4 . Patients severe liver kidney dysfunction chronic disease important organ exclude . 5 . Patients active autoimmune disease require immunosuppressive therapy exclude . 6 . Patients require corticosteroid ( inhale ) exclude . 7 . Patients severe disease situation improper research exclude , include neurologic disease , mental disease , immune disease , metabolic disease , contagious disease . 8 . Pregnant and/or lactate woman exclude . 9 . Patients biotherapy past 4 week . 10 . Patients participate participated clinical trial late 30 day exclude . 11 . Patients subject suffer disease affect understand informed consent comply study protocol exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>mesothelin</keyword>
	<keyword>PD-1</keyword>
	<keyword>CAR T</keyword>
	<keyword>solid tumor</keyword>
</DOC>